Pro Medicus Limited (ASX:PME) shares are currently down around 1% after responding to reports of a data breach.
Pro Medicus provides medical imaging and communication systems software and services to hospitals, imaging centres and healthcare groups globally. In 2009 it acquired Visage Imaging and transformed it into a global provider of medical imaging solutions.
Response to data breach speculation
Today, Pro Medicus responded to speculation overnight about a data breach. This breach impacted its subsidiary Visage Imaging.
The company confirmed that there was unauthorised access of “a single email inbox by an unknown third party in July 2025”. Pro Medicus said that when it became aware of the incident it promptly engaged external cybersecurity experts, secured the inbox and the incident was contained.
Pro Medicus undertook a comprehensive analysis of the unauthorised access and confirmed it was isolated and confined to a single mailbox, with no access to any client systems or patient data. The company noted that no Pro Medicus systems, products or databases were accessed or affected.
The impact of the data breach
Pro Medicus sad that it has not had any financial loss or operational impact from the incident.
However, it was discovered that the personally identifiable information (PII) of around 100 current and former Pro Medicus employees could have been accessed.
The company said that it has notified all of these people to inform them of the possible access to their personal data.
Pro Medicus said that based on the analysis, it does not believe that any material or commercially sensitive information was accessed. The company also noted that it notified all relevant government authorities.
Should this influence Pro Medicus shares?
Pro Medicus seems to be doing all the right things in relation to the incident, and it seems that the impact will be small. It is unfortunate for the employees who may have had their data accessed though.
The ASX listed healthcare software company is often seen as one of the best companies on the ASX. It has a high valuation to match. But it does still look expensive on a price/earnings (P/E ratio) basis.
Pro Medicus shares are down 20% since 22 September 2025, so it is substantially cheaper than it was. It continues to win big contracts so it could still be a solid long term buy today. However, there are other ASX growth shares I’m interested in.
